β2-Adrenergic Receptor-Mediated Histamine H1 Receptor Down-Regulation: Another Possible Advantage of β2 Agonists in Asthmatic Therapy
-
- Kawakami Nozomi
- Department of Pharmacology, Faculty of Pharmaceutical Sciences, The University of Tokushima
-
- Miyoshi Katsuhiro
- Department of Pharmacology, Faculty of Pharmaceutical Sciences, The University of Tokushima
-
- Horio Shuhei
- Department of Pharmacology, Faculty of Pharmaceutical Sciences, The University of Tokushima
-
- Fukui Hiroyuki
- Department of Pharmacology, Faculty of Pharmaceutical Sciences, The University of Tokushima
書誌事項
- タイトル別名
-
- .BETA.2-Adrenergic Receptor-Mediated Histamine H1 Receptor Down-Regulation: Another Possible Advantage of .BETA.2 Agonists in Asthmatic Therapy
- ベータ 2 Adrenergic Receptor Mediated Histamine H1 Receptor Down Regulation Another Possible Advantage of ベータ 2 Agonists in Asthmatic Therapy
この論文をさがす
抄録
To clarify heterologous regulation of a receptor is important in considering medication. Histamine constricts the airway smooth muscle through the action to the H1 receptor (H1R), which contributes to asthma. β2-Adrenergic receptor (β2R) agonists are widely used in asthmatic therapy for their bronchodilating effects. In this study, we investigated the effect of β2R activation on the H1R function using Chinese hamster ovary cells stably co-expressing human histamine H1R and β2R (CHO-H1/β2 cell). The stimulation of β2R resulted in the decrease of H1R in the membrane. Heterologous H1R down-regulation was significantly reversed in the presence of the cyclic AMP-dependent protein kinase (PKA) inhibitor KT5720. Since phosphorylation of G protein-coupled receptor (GPCR) by second messenger-dependent kinases, is proposed to be a key step initiating heterologous receptor desensitization, we examined whether heterologous H1R down-regulation was accompanied by H1R phosphorylation. H1R was phosphorylated by β2R stimulation; however, a PKA inhibitor did not inhibit heterologous H1R phosphorylation. Our results suggest that H1R was heterologously regulated by β2R. Not only a direct action of β2R agonist to β2R causing bronchodilation but also indirect action that reduces the number of H1R responsible for bronchoconstriction might contribute to a decrease in the bronchial resistance, which proposes another possible advantage of β2R agonists for asthmatic medication.<br>
収録刊行物
-
- Journal of Pharmacological Sciences
-
Journal of Pharmacological Sciences 94 (4), 449-458, 2004
公益社団法人 日本薬理学会
- Tweet
キーワード
詳細情報 詳細情報について
-
- CRID
- 1390001205176427136
-
- NII論文ID
- 10012892051
-
- NII書誌ID
- AA11806667
-
- ISSN
- 13478648
- 13478613
- http://id.crossref.org/issn/0015749X
-
- NDL書誌ID
- 6917398
-
- PubMed
- 15107586
-
- 本文言語コード
- en
-
- データソース種別
-
- JaLC
- NDL
- Crossref
- PubMed
- CiNii Articles
-
- 抄録ライセンスフラグ
- 使用不可